A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

Although Novo Nordisk and Eli Lilly are the main players in the GLP-1 arena, a number of other pharmaceutical companies are ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...